Skip to main content

Table 2 Expected number of newly diagnosed U.S. patients by HLA-1 type and cancer entity

From: Identification and ranking of recurrent neo-epitopes in cancer

A)             
Cancer entityStudyNumber of patientsHLA-A*01:01 (7.61%)HLA-A*02:01 (20.36%)HLA-A*03:01 (6.60%)HLA-A*11:01 (4.37%)HLA-B*07:02 (6.51%)HLA-B*08:01 (4.80%)HLA-B*15:01 (4.46%)HLA-C*04:01 (16.69%)HLA-C*06:02 (5.72%)HLA-C*07:01 (9.28%)HLA-C*07:02 (15.39%)
Bladder Urothelial CarcinomaBLCA6930034063819715214211289223376596383
Invasive Breast CarcinomaBRCA2048001101090461199108375120482141123051234
Cervical Squamous Cell CarcinomaCESC140005813516171314231422766152
Colon AdenocarcinomaCOAD15484086116287707604502223752961101916201800
Esophageal AdenocarcinomaESCA475023151261620513101232683
Glioblastoma MultiformeGBM3204717370038533
Head & Neck Squamous Cell CarcinomaHNSC580004320811245811181301136220175
Renal Clear Cell CarcinomaKIRC576001370230080010026
Papilliary Renal Cell CarcinomaKIRP8064060300029000
Acute Myeloid LeukemiaLAML1350077115084900048973
Hepatocellular CarcinomaLIHC297001249613184691276869112174
Lung Squamous Cell CarcinomaLUSC660001816423281682821377593151172366
Serous Ovarian CancerOV1680026243310152143991436
Prostate AdenocarcinomaPRAD26000012085269693450701753876281202
MelanomaSKCM75000264978901817936861530203218643810002457
Stomach AdenocarcinomaSTAD2500047172566626830206114166130
Thyroid CancerTHCA46400394000014000044
Endometrial CarcinomaUCEC550009422804817501369290493222285616021779
Total 11619585904169364858303325171666159897365080853910116
B)             
Number of candidates in diseases  5591686433242448485055
  1. A) Expected number of patients of a given HLA-1 type who harbor at least one potentially immunogenic neo-epitope candidate for that HLA-1 type. Both the cancer incidence and the allele frequency are estimated for the U.S. population. The probability that a patient carries at least one variant from the set of neo-epitope candidates is computed under the assumption that the occurrence of variants in a cancer patient stems from statistically independent events. B) Number of neo-epitope candidates identified in the 18 studies shown in A, which are predicted to be strong binders to the corresponding HLA-1 type